RxDoctor Payments DataLook up a doctor →

Jenniffer Bates, APRN

Adult Health · Winter Garden, FLNPI 1720463771

Payments from drug & device makers

$19,040in general payments, 2019–2025

Across 529 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GSK$3K
  • Grifols USA, LLC$2K
  • Boehringer Ingelheim$2K
  • United Therapeutics Corporation$1K
  • Actelion Pharmaceuticals US, Inc.$973
  • plus $6K from 31 others

What the payments were for

  • Consulting fees$7444%
  • Food & beverage$17,93294%
  • Education$3642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,040 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$35,236
Medicare patients
125
Services billed
663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter125$92,684
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$25,112
Spiriva RespimatTiotropium Bromide15$12,157
Breo ElliptaFluticasone/Vilanterol19$11,430
SymbicortBudesonide/Formoterol Fumarate39$9,707
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,246
Albuterol Sulfate HfaAlbuterol Sulfate91$1,924
BreynaBudesonide/Formoterol Fumarate13$1,500
Montelukast Sodium94$700
Fluticasone Propionate28$332
Azelastine Hcl15$259
Prednisone72$224
Azithromycin20$125
Doxycycline Monohydrate11$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$3,378$104,114144 claims
AstraZenecaBreztri Aerosphere, Symbicort$4,059$34,81975 claims
Boehringer IngelheimSpiriva Respimat$1,583$12,15715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.

Other adult health in Winter Garden

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →